24 Two ST309 Pseudomonas aeruginosa clinical isolates resistant to carbapenems and 25 newer β-lactam/β-lactamase inhibitor combinations were found to harbor the extended 26 spectrum beta-lactamases GES 19 and 26 genetically clustered in tandem. The 27 combination of ceftazidime/avibactam plus aztreonam achieved cure in one patient. 28 Phylogenetic analysis suggests that ST309 P. aeruginosa carrying tandem GES are an 29 emerging lineage in the United States.
Introduction 45
The Centers for Disease Control and Prevention has identified multidrug-resistant (MDR) 46
Pseudomonas aeruginosa as a serious threat and treatment of such isolates often requires the 47 use of drugs with significant toxicities [1] . Carbapenem resistance in P. aeruginosa in the USA is 48 mostly mediated by non-carbapenemase mechanisms [2] . In response, novel therapeutics such 49 as ceftolozane/tazobactam (C/T), which is stable to the pseudomonal AmpC β-lactamase and 50 less susceptible to porin loss and drug efflux, have entered the clinic to combat this threat [3] . 51
Although C/T remains broadly active against most clinical isolates of carbapenem-resistant P. 52 aeruginosa, resistance associated with mutations in AmpC or the expression of acquired β-53 lactamases has been described [4] [5] [6] . 54
The Guiana Extended Spectrum β-lactamase (GES) enzyme was first isolated from a 55 Klebsiella pneumoniae obtained from a rectal swab of an infant in Cayenne, French Guiana [7] 56 and, since then, 32 variants have been identified. In general, these enzymes confer resistance 57 to penicillins, including ureidopenicillins, and oxyimino-cephalosporins, but show less activity 58 against aztreonam and imipenem [7, 8] . Nonetheless, specific substitutions can significantly 59 alter this susceptibility profile, including G243A, which improves activity against aztreonam, and 60 G170S, conferring increased carbapenem hydrolyzing activity [9] . These enzymes are often 61 found in association with class 1 integrons, a gene cassette acquisition system known to harbor 62 multiple antimicrobial resistance determinants associated with mobile genetic elements [ Medicines Co.) at 2 µg/mL. This concentration was selected to mimic the serum nadir of 95 avibactam and vaborbactam from human PK/PD data. Antimicrobial susceptibility testing for the 96 Escherichia coli TG-1 mutants was performed in triplicate by inducing strains with 1 mM IPTG 97 for 2 hours prior to plating on Mueller-Hinton agar plates previously spread evenly with 40 µL of 98 100 mM IPTG. E-test strips (Biomerieux) for each antimicrobial were applied and MICs were 99 read after 24 hours of incubation at 37° C. MICs for CZA alone were determined by broth 100 microdilution with a standard inoculum prepared from the induced cultures into fresh MH broth 101 without IPTG. 102
Whole genome sequencing and P. aeruginosa phylogenetics. Genomic DNA was extracted 103 from 2 mL of overnight growth in BHI broth using the DNeasy Blood and Tissue kit (Qiagen). 104
Genome sequencing of the two isolates was performed on a Miseq platform using Illumina 105 technology, and with MinION (Oxford Nanopore Technologies, United Kingdom) for long reads. 106
Sequence data have been deposited in the NCBI database (Bioproject: PRJNA414583). 107
Resistance detection, polymorphism analysis, and reconstruction of the phylogenetic tree were 108 performed using a custom pipeline. A detailed description of the analysis can be found in the 109 supplementary material. To study the phylogenetic relationships between the isolates with other 110 P. aeruginosa genomes, all assembled genomes of P. aeruginosa available at the NCBI 111 genome database were downloaded and the MLST was obtained using the mlst tool. Nine 112 additional ST309 genomes were identified, and PAO1 (GCA_000006765.1), PA_D1 113 (GCA_001721745.1), L10 (GCA_002223805.1), M18 (GCA_000226155.1) and FRD1 114 (GCA_000829885.1) from the STs 539, 1971, 253, 1239 and 111 respectively, were used as 115 references (Supplementary Fig. 1) . 116 117 118 6
Results and Discussion 119
Two patients admitted to separate hospitals in a large urban hospital network developed 120 bacteremia due to MDR-P. aeruginosa. In the first case, the patient had two weeks of prior 121 exposure to cefepime, metronidazole, and vancomycin, then meropenem for a complicated 122 intra-abdominal infection before isolation of a MDR-P. aeruginosa (PA_HTX1 , Table 1 in the presence of avibactam. The patient was started on ceftazidime/avibactam 1.5 grams 129
given after hemodialysis with aztreonam, 2 grams IV daily and was ultimately cured with 130 complete resolution of abdominal abscesses after 105 days of therapy. In the second case, the 131 patient had bronchoalveolar lavage cultures positive for Escherichia coli, and received five days 132 of meropenem, before developing MDR-P. aeruginosa pneumonia with a similar antimicrobial 133 susceptibility profile to PA_HTX1 (PA_HTX2 , Table 1 and Supplementary Table 2 ). The 134 patient received colistin, meropenem and three doses of ceftolozane/tazobactam, but developed 135 bacteremia despite antibiotics and ultimately died due to the infection. An epidemiologic 136 investigation within the hospital system did not reveal a link between the two patients, and there 137 was no shared intensive care unit staff or equipment between the two hospitals during the 138 period of patient admissions. 139
We performed whole genome sequencing on PA_HTX1 and 2. Both isolates were 140 identified as sequence type 309 and carried a chromosomal class 1 integron with multiple 141 resistance determinants, including blaGES-19 and blaGES-26 ( Fig. 1A, Supplementary Table 3 ). To 142 determine if this tandem carriage of GES β-lactamases was present in other ST309 P. 7 aeruginosa, we performed a search of the assembled P. aeruginosa genomes available in the 144 NCBI database. Eleven ST309 P. aeruginosa (including the two patient isolates in this study) 145 were identified. Interestingly, a cluster of five ST309 isolates of clinical origin harboring tandem 146 blaGES genes from the United States and Mexico, (isolated from 2006 to 2017), appear to form a 147 distinct group (Fig. 1B) . Indeed, GES enzymes seem to be an important contributor to 148 carbapenem resistance in P. aeruginosa from Mexico with a prevalence of 30.6% [11] . An 149 analysis of the integron and surrounding genomic context revealed the Houston isolates 150 possessed an OXA-2 β-lactamase and aminoglycoside modifying enzymes not present in the 151
Mexican isolates (Fig. 1C) . In addition, the strains possess a high degree of sequence identity, 152 suggesting a close relationship between the isolates, although several gaps in the genomic 153 alignment of the Houston strains are likely driven by phage and mobile genetic elements (Fig  154   1D) . 155
To investigate the genetic bases of the MDR-phenotype, we performed a single 156 nucleotide polymorphism analysis of genes associated with antimicrobial resistance using P. 157 aeruginosa PAO1 as the reference strain ( Supplementary Table 4 ). The ampC gene for both 158 PA_HTX strains codes for the PDC-19a variant, and the polymorphisms identified in ampR, 159 ampD, and ampG have been previously reported in both wild type and resistant strains. The 160 sequences of the ampD homologues ampDh2 and ampDh3, as well as dacB, which encodes a 161 low molecular weight penicillin-binding protein associated with AmpC expression, were identical 162 to PAO1. The oprD gene was disrupted by insertion of ISPa1328, an IS256 family element that 163 truncated the first 126 base pairs of oprD including the start codon. This is predicted to result in 164 loss of oprD expression and likely contributes to the carbapenem resistance phenotype seen in 165 these isolates. In addition, both HTX isolates possessed a mutation predicted to result in a 166 deletion of 6 amino acids (residues 189-194) near the C-terminal end of MexZ, the repressor of 167 the MexXY efflux pump. This region lies at the dimerization interface of MexZ, and in this 168 context we hypothesize that loss of these residues may lead to upregulation of the MexXY efflux 169 pump [14] . Mutations in gyrA and parC seen in these isolates have been previously linked to 170 decreased susceptibility to fluoroquinolone antibiotics [2] . 171
The PA_HTX isolates were resistant to all available β-lactams, including the novel 172 combinations of C/T, CZA and meropenem/vaborbactam ( Table 1) To evaluate the spectrum of the integron encoded β-lactamases, blaGES-19, blaGES-26, and 185 blaOXA-2 from PA_HTX1 were cloned individually, and blaGES-19 and blaGES-26 in tandem, into E. 186 coli TG-1 using an inducible vector (pBA169) that responds to isopropyl β-D-1-187 thiogalactopyranoside (IPTG) [13] ( Table 1) . The presence of blaGES-19, blaGES-26, and blaOXA-2 188 alone led to modest increases in MIC for ATM, cefepime (FEP), CZA (GES only) and C/T, but 189 not MEM, as compared to TG-1 carrying empty pBA169. In contrast, the presence of both 
